Evidence map›Paper›PMID 33983492›Full record

ArticleBreast cancer research and treatment2021

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.

A J Eustace, S F Madden, J Fay, D M Collins, E W Kay, K M Sheehan, S Furney, B Moran, A Fagan, P G Morris and 13 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01485926 (A Phase II Neo-adjuvant Study Assessing TCH), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01485926 phase2completednot on this map

A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.

TypeinterventionalSponsorCancer Trials IrelandRan2010 to 2018Enrolled120ConditionsBreast CancerArmsDocetaxel, Carboplatin and Trastuzumab, Docetaxel, Carboplatin, Trastuzumab and Lapatinib
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

A J EustaceNational Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland. alex.eustace@dcu.ie.ORCID http://orcid.org/0000-0002-4092-1360
S F MaddenData Science Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.
J Fay *Department of Histopathology, Royal College of Surgeons in Ireland, Dublin, Ireland.
D M CollinsNational Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
E W KayDepartment of Histopathology, Royal College of Surgeons in Ireland, Dublin, Ireland.
K M SheehanDepartment of Histopathology, Royal College of Surgeons in Ireland, Dublin, Ireland.
S FurneyDepartment of Physiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
B MoranConway Institute, University College Dublin, Dublin, Ireland.
A FaganDepartment of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
P G MorrisDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
A TeiserskieneCancer Trials Ireland, Dublin, Ireland.
A D HillDepartment of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
L GroganDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
J M WalsheDepartment of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
O BreathnachDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
C PowerDepartment of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
D DukeDepartment of Radiology, Beaumont Hospital, Dublin, Ireland.
K EganCancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland.
W M GallagherConway Institute, University College Dublin, Dublin, Ireland.
N O'DonovanNational Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
J CrownNational Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
S Toomey *Medical Oncology Group, Department of Molecular Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
B T HennessyCancer Trials Ireland, Dublin, Ireland.
Royal College of Surgeons in Ireland · IEBeaumont Hospital · IEDublin City University · IECancer Trials Ireland · IEUniversity College Dublin · IESt. Vincent's University Hospital · IE

Funding

Irish Cancer Society CCRC13GAL
6 · The paper itself

Abstract

backgroundPre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymphocyte levels with subsequent pCR, few have studied the impact of neoadjuvant therapy on the immune environment.

methodsWe performed TIL analysis and T-cell analysis by IHC on the pretreatment and 'On-treatment' samples from patients recruited on the Phase-II TCHL (NCT01485926) clinical trial. Data were analysed using the Wilcoxon signed-rank test and the Spearman rank correlation.

resultsIn our sample cohort (n = 66), patients who achieved a pCR at surgery, post-chemotherapy, had significantly higher counts of TILs (p = 0.05) but not SLs (p = 0.08) in their pre-treatment tumour samples. Patients who achieved a subsequent pCR after completing neo-adjuvant chemotherapy had significantly higher SLs (p = 9.09 × 10

conclusionsThe immune system may be 'primed' prior to neoadjuvant treatment in those patients who subsequently achieve a pCR. In those patients who achieve a pCR, their immune response may return to baseline after only 1 cycle of treatment. However, in those who did not achieve a pCR, neo-adjuvant treatment may stimulate lymphocyte influx into the tumour.

Indexed as

Breast NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesFemaleHumansLymphocytesLymphocytes, Tumor-InfiltratingPrognosisErb-b2 Receptor Tyrosine KinasesHER2-positive breast cancerNeo-adjuvant treatmentT-cellsTumour infiltrating lymphocytes

Identifiers

PMID33983492
PMCPMC8197702
OpenAlexW3161011842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.